In the News

By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]

By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]

GAP Community Connector, Paula Atkinson, was a guest writer for the Orlando Times and explained why she and GAP are committed to advancing Alzheimer’s clinical research in Black and Brown communities. My grandmother was treated for Alzheimer’s disease, but never diagnosed with it. Why? She was toldby her doctor that it would take too long […]

GAP-Net Site Kerwin Medical Center was featured in Community Impact on the rate of Alzheimer’s disease in Hispanic communities, and how they can help. As part of a nationwide study, Kerwin Medical Center is testing the efficacy of Aducanumab, a drug that helps a type of plaque in the brain and slows memory impairment caused […]

GAP-Net Site K2 Medical Research was featured in the Orlando Times speaking about the rate of Alzheimer’s in the black community, and studies they have that can help. ORLANDO – For the 580,000 Floridians who are living with Alzheimer’s disease, or for the state’s 1.1 million citizens who who serve as unpaid Alzheimer’s caregivers, one […]

GAP President John Dwyer was quoted in the Financial Times talking about how the CMS decision will limit patient access to possible life saving Alzheimer’s treatments. Eisai has warned that mandatory data collection by US health authorities could restrictpatient access to the Japanese drugmaker’s new Alzheimer’s treatment. The company said a decision by Centers for […]

GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]

GAP-Net Site The Alzheimer’s Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer’s Disease  Research Center of Albany is looking for volunteers for an Alzheimer’s clinical study, putting an emphasis on the recruitment of people of color.  While people from underrepresented communities — including those who are […]

WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]

House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]

2022 Citizen Scientist Champion Award Elevated Honoree, Bob Deady, was featured in the KU ADRC publication for his dedication to Alzheimer’s research. There’s a familiar face around the University of Kansas Alzheimer’s Disease Research Center (KU ARDC). He doesn’t have an office, or a nameplate on the door or letters behind his name. But he’s doing his […]

GAP President John Dwyer wrote an op-ed in the Dallas Examiner calling on President Biden to reverse the Centers for Medicare and Medicaid Services to cover Leqembi and future Alzheimer’s drugs and treatments. The Biden administration has a big problem on its hands. It’s sending mixed signals on new Food and Drug Administration approved Alzheimer’s […]

by Barbara Campos – Telemundo According to the conclusions of a new Alzheimer’s Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease […]

BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S., according to […]

GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.

GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials.  Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted […]

GAP President, John Dwyer, spoke to Genome Web about the closing of our Bio-Hermes study, and what the results may do for the future of Alzheimer’s research. The Global Alzheimer’s Platform (GAP) has completed a first-of-its-kind cross sectional study comparing the performance of Alzheimer’s diagnostic assays. Topline results are expected in July of next year, […]

GAP-Net site, El Faro Health & Therapetuics was featured in AARP on the work they are doing to bring Alzheimer’s research to the Latino and Starr County communities. On a gloomy mid-November morning in 2021, Jessica Cantú stood in the parking lot outside a health center in the rural border community of Starr County, Texas, […]

In honor of World Alzheimer’s Day, the Global Alzheimer’s Platform Foundation continues to push for diversity in Alzheimer’s clinical trials WASHINGTON, DC, Sept. 20, 2022 — In recognition of World Alzheimer’s Day (Sept. 21), the Global Alzheimer’s Platform Foundation (GAP) is bringing its mobile research unit into Orlando-area communities. This continues GAP’s work toward increasing participation of […]

GAP President John Dwyer spoke with Duane Schulthess on the Vital Health podcast about everything from the work that GAP is doing with the Davos Alzheimer’s Collaborative and the CEOI and the CMS decision several months ago. “It’s just a fact that there are a lot of us that are sick with Alzheimer’s. It is the […]

GAP-Net Site, iResearch Atlanta, hosted an event to brainstorm ways to educate community members on Alzheimer’s and other dementia related diseases. Near the end of July, 10 individuals from the Global Alzheimer’s Platform Foundation (GAP), MapHabit, Collaborative Real Estate, and 250 E Ponce’s very own iResearch Atlanta were exclusively invited to gather over complimentary lunch […]

GAP partner, Genetech, is working with us on our Bio-Hermes study to increase diversity in Alzheimer’s clinical trials. Missing a trial goal in Alzheimer’s disease is a pretty common occurrence—see crenezumab, for the latest. But Genentech’s latest reported miss was something different. The Roche unit wanted to build a clinical trial program for its lead candidate […]

Dr. Richard Holub from GAP-Net site Neurological Associates of Albany talks about his commitment to finding a cure for Alzheimer’s disease and says he won’t be retiring anytime soon. Dr. Richard Holub has spent the past 40 years dedicated to Alzheimer’s research. He has treated thousands of Alzheimer’s patients and completed more than 125 clinical […]